Safety profile of gemcitabine a novel anticancer agent, in non-small cell lung cancer

Anti-Cancer Drugs

Volumn 8, Issue 6, 1997, Pages 582-587

  Cortes Funes, Hernan ^a   Martin, Christophe ^b   Abratt, Raymond ^c   Lund, Birthe ^d  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b ELI LILLY AND COMPANY   (United States)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

^d Rigshospitalet   (Denmark)

Author keywords

Chemotherapy; Drug therapy; Non small cell lung carcinoma

Indexed keywords

GEMCITABINE;

ALOPECIA; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CARDIOTOXICITY; DRUG SAFETY; FEVER; FLU LIKE SYNDROME; HAIR LOSS; HUMAN; INFECTION; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; NEUROTOXICITY; PRIORITY JOURNAL; SKIN TOXICITY;

ADOLESCENT; ADULT; AGED; ALOPECIA; ANEMIA; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, NON-SMALL-CELL LUNG; DEOXYCYTIDINE; DIARRHEA; DYSPNEA; EDEMA; FEVER; HEART; HUMANS; KIDNEY; LIVER; LUNG NEOPLASMS; MIDDLE AGED; NAUSEA; VOMITING;

EID: 0030867348     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199707000-00005     Document Type: Article

References (21)

1. Walling J. Chemotherapy of advanced non-small cell lung cancer. Respir Med 1994; 88: 649-57.
2. Souhami RL, Stewart LA, Arriagada R, Parmar M, Le Chevalier T, Pignon JP. A data-based meta-analysis of randomised trials of chemotherapy versus best supportive care (BSC) in advanced non-small cell lung cancer (NSCLC). Lung Cancer 1994; 11: 25 (abstr).
3. Bhalla K, Maclaughlin W, Cole J, Arlin Z, Birkhofer M, Graham G. Continuously administered 2′,2′-difluorodeoxycytidine (dFdC) and deoxycytidine (dCyd): a potentially selective cytotoxic regimen toward human leukemic myeloid progenitors in culture. Proc Am Ass Cancer Res 1988; 28: 348 (abstr 1385).
4. Bouffard DY, Momparler LF, Momparler RL. Comparison of antineoplastic activity of cytosine arabinoside and 2′,2′-difluorodeoxycytidine on human myeloid, T-cell and B-cell leukemic cells. Eur J Pharmacol 1990; 183: 161 (abstr 32).
5. Chubb S, Heinemann V, Novotny L, et al. Metabolism and action of difluorodeoxycytidine (dFdC) in human leukemia cell. Proc Am Ass Cancer Res 1987; 28: 324 (abstr 1282).
6. Fujita F, Fujita M, Inaba H. Effects of a new anticancer agent LY188011 on human cancer xenografts in nude mice. Forty-eighth Annual Meeting of the Japanese Cancer Association, Nagoya, Japan. October 1989: 23-5 (abstr 1938).
7. Grindey GG, Boder, GB, Hertel LH, et al. Antitumor activity of 2′,2′-difluorodeoxycytidine (LY 188011). Proc Am Ass Cancer Res 1986; 27: 296 (abstr 1775).
8. Plunkett W, Chubb S, Nowak B, Hertel L, Grindey GB. Increased cytotoxicity and therapeutic activity of 2′,2′-difluorodeoxycytidine over cytosine arabinoside (ara-C) in L1210 leukemia. Proc Am Ass Cancer Res 1988; 29: 352 (abstr 1402).
9. Tanayanagi C, Takauji R, Ueda T. Action mechanism of difluorodeoxycytidine (dFdC), a new ara-C derivative. Acta Hematol Jpn 1990; 53: 76 (abstr 132).
10. Carmichael J, Possinger K, Phillip P, et al. Advanced breast cancer: a phase II trial with gemcitabine. J Clin Oncol 1995; 13: 2731-6.
11. Carmichael J, Fink U, Russell RCG, et al. Phase II study of gemcitabine in patients with advanced pancreatic cancer. Eur J Cancer 1993; 29A: S101 (suppl 6, abstr 541).
12. Casper ES, Green MR, Kelsen DP, et al. Phase II trial of gemcitabine (2′,2′difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs 1994; 12: 29-34.
13. Lund B, Hansen OP, Theilade K, Hansen M, Neijt JP. Phase II study of gemcitabine (2′,2′-difluorodeoxycitidine) in previously treated ovarian cancer. An update. J Natl Cancer Inst 1994; 86: 1530-3.
14. Cormier Y, Eisenhauer E, Muldal A, et al. Gemcitabine is an active new agent in previously un-treated extensive small cell lung cancer. A study of the National Cancer Institute of Canada Clinical Treatment Group. Ann Oncol 1994; 5: 283-5.
15. Pollera CF, Ceribelli A, Crecco M, Calabresi F. Weekly gemcitabine in advanced bladder cancer: a preliminary report from a phase I study. Ann Oncol 1994; 5: 182-4.
16. Catimel G, Vermorken JB, Clavel M, De Mulder P, Judson I, Sessa C. A phase II study of gemcitabine (LY188011) in patients with advanced squamous cell carcinoma of the head and neck. Ann Oncol 1994; 5: 543-7.
17. Abratt RP, Bezwoda WR, Folkson G, Goedhals L, Hacking D, Rugg TA. Efficacy and safety profile of gemcitabine in non-small cell lung cancer: a phase II study. J Clin Oncol 1994; 8: 1535-40.
18. Anderson H, Lund B, Bach F, Thatcher N, Walling J, Hansen HH. Single-agent activity of weekly gemcitabine in advanced non-small cell lung cancer: a phase II study. J Clin Oncol 1994; 9: 1821-6.
19. Gatzemeier U, Shepherd F, Le Chevalier T, et al. A multicenter phase II trial with gemcitabine in non-small cell lung cancer (NSCLC). Lung Cancer 1994; II (suppl 1): 121 (abstr 461).
20. Kaye SB. Gemcitabine: current status of phase I and II trials (editorial). J Clin Oncol 1994; 12: 1527-31.
21. Hatty S. Elevations of LFTs with gemcitabine are mild, transient and rarely result in withdrawal or dose adjustment. ECCO8 1995 (abstr 939).